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to disability progression rate. ConClusions: The incremental cost effectiveness 
ratio of 17.433 € is considerably below the threshold usually accepted for financing 
medicines in Portugal (around 30.000 € /QALY). Dimethyl Fumarate should be seen 
as a cost-effective therapy for the Portuguese setting.
PND57
Cost-EffECtivENEss ANAlysis of PEgiNtErfEroN BEtA-1A iN itAliAN 
rElAPsiNg rEmittiNg multiPlE sClErosis mANAgEmENt
Iannazzo S1, Santoni L2, Saleri C2, Puma E2, Vestri G2, Giuliani L1, Canonico PL3,  
Centonze D4
1SIHS Health Economics Consulting, Torino, Italy, 2Biogen, Milan, Italy, 3Università del Piemonte 
Orientale, Novara, Italy, 4Università Tor Vergata, Rome, Italy
objeCtives: Peginterferon beta-1a is indicated for the treatment of adult relaps-
ing remitting multiple sclerosis (RRMS) patients. The efficacy and safety of sub-
cutaneous (SC) peginterferon beta-1a (PEGIFN beta-1a) was demonstrated in the 
randomised double blind Phase 3 placebo-controlled ADVANCE trial. We assessed 
the cost-effectiveness of PEGIFN beta-1a compared with other injectable first-line 
RRMS treatments in Italy. Methods: The analysis was developed through a Markov 
model with lifetime simulation in the perspective of the Italian National Healthcare 
Service (NHS). Outcomes measurements included life years (LYs), quality adjusted 
life years (QALYs), lifetime costs, and incremental cost-effectiveness ratio (ICER). 
The natural progression of disease used in the model was based on previously 
published literature and modelling exercises. Treatment efficacy (reduction of 
disability progression and reduction of relapse rate) was derived from published 
mixed treatment comparison. Unit costs were based on Italian 2015 prices and 
tariffs, and the published literature. A 3.5% discount rate was applied to costs and 
benefits. One-way and probabilistic sensitivity analyses were developed and cost-
effectiveness acceptability curves generated. Results: PEGIFN beta-1a provided 
numerically longer patient survival (19.94 vs. 19.68-19.81 discounted LYs, respec-
tively), and QALY (9.07 vs 8.06 - 8.55 discounted QALY, respectively). The ICER for 
SC PEGIFN beta-1a vs. IM interferon beta-1a 30mcg; SC interferon beta-1a 22mcg; 
SC interferon beta-1b 250mcg; or glatiramer acetate 20mcg was € 11,018; € 12,504; 
€ 10,477; € 16,599; € 21,536 per QALY respectively. Peginterferon beta-1a dominated 
interferon beta-1a 44mcg. The outcomes of the sensitivity analyses confirmed the 
robustness of these results. ConClusions: PEGIFN beta-1a was dominant vs SC 
interferon beta-1a 44mcg and cost-effective when compared with other approved 
first-line injectable treatments for RRMS in Italy. The ICERs fall well below the com-
monly accepted thresholds of € 30,000 - € 50,000 per QALY gained demonstrating that 
PEGIFN beta-1a is a cost effective treatment.
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objeCtives: To examine the economic burden and health care utilization for 
patients diagnosed with Parkinson’s disease using linked data from Medicare and 
the Long Term Care (LTC) Minimum Data Set (MDS). Methods: Patients were 
included in the study if they had at least one diagnosis claim for Parkinson’s disease 
(International Classification of Diseases, 9thRevision, Clinical Modification code 332.
xx) during the identification period (01JUL2008-31DEC2010). The first Parkinson’s dis-
ease diagnosis claim date was designated as the index date. Patients were required 
to be age ≥ 65 and have continuous health plan enrollment with medical benefits 
for 6 months pre- and post-index date. Residents in a LTC facility were defined as 
study patients using two quarterly assessments recorded in the MDS during the 
6-month baseline period. Demographic and clinical characteristics and follow-up 
health care costs and utilizations were described. Results: After 1:1 matching, 
1,620 patients were included in each group (disease and control patients), and the 
baseline characteristics were well-balanced. Patients with Parkinson’s disease 
were more likely to have inpatient stays (14.26% vs. 9.51%, p< 0.0001), outpatient 
visits (47.72% vs. 41.11%, p= 0.0002), skilled nursing facility (SNF) visits (20.37% vs. 
4.51%, p< 0.0001), hospice visits (8.64% vs. 1.36%, p< 0.0001), and part D pharmacy 
visit (62.65% vs. 53.33%, p< 0.0001). Compared to control patients, higher all-cause 
health care costs were also observed for Parkinson’s disease patients, including 
inpatient costs ($2,451 vs. $1,301, p< 0.0001), SNF costs ($2,503 vs. $778, p< 0.0001), 
hospice costs ($1,164 vs. $245, p< 0.0001), total outpatient costs ($4,477 vs. $1,304, 
p< 0.0001), pharmacy costs ($695 vs. $1,399, p< 0.0001) and total costs ($9,775 vs. 
$5,314, p< 0.0001). ConClusions: During a period of 12 months, patients diag-
nosed with Parkinson’s disease had higher health care utilization and costs than 
matched control patients.
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objeCtives: To evaluate the cost-utility of modern anti-Parkinson drugs in mono-
therapy early stages of Parkinson’s disease (PD) in the Russian Federation. Methods: 
For analysis of market data regarding PD treatment products we used IMS 
Health Russia database (2014). The target population was newly diagnosed 
PD patients over 60 years in the early clinical stages according to Hoehn and Yahr 
functional scale (HY I-III stage). Comparison drugs: pramipexole ER, piribedil CR, 
ropinirole ER and rasagiline. Utility effect of anti-Parkinson drugs was evaluated 
by quantitative scale UPDRS – Unified Parkinson’s Disease Rating Scale, part II 
(daily activities) and III (the severity of motor disorders). In the analysis we took 
into account the costs associated with adverse drugs reactions (ADR). Discounting 
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objeCtives: Relapsing-remitting multiple sclerosis (RRMS) is characterized by 
periods of relapse and remission, leading to progressive accumulation of disability. 
Disease-modifying treatments (DMTs) are used in treatment of MS to reduce the 
frequency of relapses and disease progression. The study objective was to compare 
the cost effectiveness of dimethyl fumarate with teriflunomide for treatment of 
RRMS in a Danish setting from a healthcare and societal perspective. Methods: In 
a cohort based Markov model patients progress through a series of disability states 
based on the Expanded Disability Status Scale (EDSS). At any time, patients have 
fixed probabilities of progression and relapse dependent on RRMS or secondary 
progressive MS (SPMS) status and the EDSS score. Mixed treatment comparisons 
determined the clinical efficacy of the treatment options that in the model act to 
delay the progression of the disease and reduce the relapse frequency in patients 
with RRMS. The model uses one-year cycles, and the base case time frame of the 
analysis was 30 years. Healthcare and societal costs (including productivity losses) 
and QALYs for each patient are directly linked to the time the patient spends in each 
EDSS state. Results: In the base case, treatment with dimethyl fumarate compared 
with teriflunomide is associated with a QALY-gain of 0.21 QALYs, at lower healthcare 
(DKK -87,547) and societal costs (DKK -132,524), implying that dimethyl fumarate is 
a dominant strategy. Probabilistic sensitivity analyses were performed, showing that 
dimethyl fumarate dominates from a healthcare and societal perspective in 67.6% and 
72.9% of 5,000 simulations, respectively. One-way sensitivity analyses showed that 
dimethyl fumarate is costsaving from a healthcare and societal perspective at a yearly 
drug-cost difference up to DKK 46,000 and DKK 58,000, respectively. ConClusions: 
The analysis demonstrates that dimethyl fumarate is a cost-effective and cost saving 
treatment alternative from a Danish healthcare and societal perspective.
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objeCtives: To assess the cost-effectiveness of fingolimod as a second-line therapy 
for patients with highly active relapsing-remitting multiple sclerosis using a Markov 
model applied to Greece. Methods: The analysis was undertaken from the perspec-
tive of the Greek NHS and the model was populated with data drawn from the litera-
ture and national published sources. Two cohorts of patients, one for the intervention 
and one for the comparator treatment sequence, are simulated in the model over a 50 
year time horizon. Each patient in a given cohort is treated with four lines of treatment 
or removed from treatment due to death. The analysis is based on the subgroup of 
highly active relapsing-remitting MS patients despite treatment with a previous DMT 
as this represents fingolimod’s main target population. The discount rate was 3.5% 
per year. Extensive sensitivity analysis was also undertaken. Results: This analysis 
has shown that the use of fingolimod as second-line treatment compared to DMF in 
these patients results in an incremental cost-effectiveness ratio of € 32,939 per QALY 
gained over a patient’s lifetime for Interferon-beta1-aSC – Fingolimod – BSC – BSC 
compared to Interferon-beta1-aSC – DMF – BSC – BSC, in € 33,783 for Interferon-beta1-
aIM – Fingolimod – BSC - BSC compared to Interferon-beta1-aIM – DMF – BSC - BSC and 
in € 32,998 for Glatiramer acetate – Fingolimod – BSC – BSC compared to Glatiramer 
acetate – DMF – BSC – BSC. The above estimates did not vary substantially across a 
range of assumptions investigated within the sensitivity analyses. ConClusions: 
The use of fingolimod as second-line treatment compared to DMF in patients with 
highly active relapsing-remitting MS in a Greek health care setting results in long-
term clinical benefit and it is associated with a modest incremental cost-effectiveness 
ratio that most decision makers would consider acceptable especially for such a 
disabling disease.
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objeCtives: This study aims to assess the cost-utility of delayed-release dime-
thyl fumarate (DMF; also known as gastro-resistant DMF), a new disease modify-
ing therapy (DMTs), in treatment of patients with Relapsing-Remitting MS (RRMS) 
in Portugal. Methods: A 1-year cycle Markov model based on the ScHARR MS 
Model was used to simulate disease progression, measured by Kurtzke Expanded 
Disability Status Scale (EDSS), relapses, and conversion to secondary-progressive MS 
(SPMS). It was assumed that patients could discontinue first line treatment (DMF or 
glatiramer acetate) and switch to a second line, but would stop any treatment after 
conversion to SPMS or progression to EDSS7. Clinical inputs for active treatments 
(disability progression, relapse rate and discontinuation of ITT population) were 
estimated on a mixed treatment comparison while natural history was based on 
DMF clinical trials and London Ontario database. Utility weights for patients and 
caregivers were derived from DMF clinical trials and the UK-MS Survey. Resource 
consumption by EDSS and due to relapses was based on published literature 
relevant to the Portuguese setting. Unit costs were obtained from official sources. 
The analysis was conducted from the societal perspective, assuming a time horizon 
of 50 years and a discount rate of 5%, for both costs and benefits. Results: When 
compared to glatiramer acetate, DMF was associated with delay in progression and 
reduction in annualized relapse rate, resulting in a gain of 0.39 quality adjusted life 
years (QALYs), but implying a cost increase of 8.971 € . The incremental cost per 
QALY is thus 17.433 € . Sensitivity analysis shows that results are more sensitive 
